Skip to main content
SpringerLink
Log in

Merit in retaining ICER alongside net benefit

  • Comment
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. see PharmacoEconomics & Outcomes News 854 p2; 803475935

Reference

  • O'Mahony JF. Does Cost-Effectiveness Analysis Really Need to Abandon the Incremental Cost-Effectiveness Ratio to Embrace Net Benefit? PharmacoEconomics : 15 Jun 2020. Available from: URL: https://doi.org/10.1007/s40273-020-00931-5

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Merit in retaining ICER alongside net benefit. PharmacoEcon Outcomes News 856, 19 (2020). https://doi.org/10.1007/s40274-020-6919-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6919-x

Search

Navigation